# US 2026/0028647 A1 · Compositions and Methods for Editing Cytoplasmic DNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028647 A1
- Document ID: US20260028647A1
- Status: Published application
- Kind: A1
- Application number: 18/875,658
- Filed: 2023-07-06
- Published: 2026-01-29
- Earliest claimed: 2022-07-07
- Applicants: The Regents of the University of California
- Inventors: Adam Joseph Schieferecke; David V. Schaffer; John E. Dueber; Juan Eduardo Hurtado Koolik
- Web page: https://patentgrep.com/patent/US20260028647A1

## CPC

- C12N 15/1131: {against viruses}
- C12N 15/902: {using homologous recombination}
- C12N 9/1252: {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/85: for animal cells
- C12N 15/907: {in mammalian cells}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/095: containing a nuclear export signal
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides systems and methods for modifying a target viral nucleic acid in the cytoplasm of a eukaryotic cell.

## Claims

### Claim 1

A method of modifying a target viral nucleic acid in the cytoplasm of a eukaryotic cell, the method comprising contacting the target viral nucleic acid with:
a) a fusion polypeptide comprising: i) a CRISPR-Cas effector polypeptide; and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase and wherein one of the two or more heterologous polypeptides comprises a nuclear export signal (NES) polypeptide; and
b) one or more guide nucleic acids, wherein one or more guide nucleic acids comprise: i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide,
wherein said contacting provides for modification of the target viral nucleic acid.

### Claim 2 (depends on 1)

The method of claim 1, wherein the fusion polypeptide does not include a nuclear localization signal (NLS).

### Claim 3 (depends on 1)

The method of claim 1, wherein the targeting region of the guide nucleic acid has a length of from about 15 nucleobases to 19 nucleobases.

### Claim 4 (depends on 1)

The method of claim 1, wherein the error-prone DNA polymerase has reduced or lacks 3′-5′ exonuclease activity.

### Claim 5 (depends on 1)

The method of claim 1, wherein the fusion polypeptide has a length of no more than about 3000 amino acids.

### Claim 6 (depends on 1)

The method of claim 1, further comprising contacting the target viral nucleic acid with a donor nucleic acid.

### Claim 7 (depends on 1)

The method of claim 1, wherein the CRISPR-Cas effector polypeptide is a type II CRISPR-Cas effector polypeptide, a type III CRISPR-Cas effector polypeptide, a type IV CRISPR-Cas effector polypeptide, a type V CRISPR-Cas effector polypeptide, or a type VI CRISPR-Cas effector polypeptide.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein the CRISPR-Cas effector polypeptide is a Cas9 polypeptide or wherein the CRISPR-Cas effector polypeptide is a variant Cas9 polypeptide that has relaxed protospacer adjacent motif (PAM) requirements, optionally wherein the variant Cas9 polypeptide comprises an amino acid sequence having at least 50% amino acid sequence identity to the amino acid sequence depicted in any one of SEQ ID NOs: 88-90 and 32.

### Claim 10 (depends on 1)

The method of claim 1, wherein the fusion polypeptide, when complexed with a guide RNA, exhibits a target mutation rate of from 10−8 to 10−2 mutations per nucleotide per viral genome replication event, from 10−6 to 10−5 mutations per nucleotide per viral genome replication event, from 10−5 to 10−3 mutations per nucleotide per viral genome replication event, or from 10−3 to 10−2 mutations per nucleotide per viral genome replication event.

### Claim at position 11

-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the CRISPR-Cas effector polypeptide is a nickase.

### Claim 15 (depends on 1)

The method of claim 1, wherein the CRISPR-Cas effector polypeptide lacks catalytic activity but retains binding to the target viral nucleic acid.

### Claim 16 (depends on 1)

The method of claim 1, wherein the target viral nucleic acid is a nucleic acid of a double-stranded DNA virus that has a genome length of from about 50 kbp to about 1.2 mbp, or from about 150 kbp to 1.2 mbp, and wherein at least part of the replication cycle of the double-stranded DNA virus occurs in the cytoplasm of the cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein the double-stranded DNA virus is a virus of a family selected from Poxviridae, Asfaviridae, Iridoviridae, Ascovirida, Phycodnaviridae, Marseilleviridae, Pithoviridae, Mimiviridae, Pandoraviridae, Molliviruses, and Faustoviruses.

### Claim 18 (depends on 1)

The method of claim 1, wherein the DNA polymerase comprises an amino acid sequence having at least 85% amino acid sequence to the DNA polymerase I amino acid sequence depicted in SEQ ID NO:1, wherein the DNA polymerase has one or more of the following: an Ala at amino acid position 424, an Asn at amino acid position 709, a Tyr at amino acid position 742, an Arg at amino acid position 759, and a His at amino acid position 796 or wherein the DNA polymerase is a DNA polymerase beta, a DNA polymerase iota, a DNA polymerase nu, a DNA polymerase eta, or a DNA polymerase kappa.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the fusion polypeptide, when complexed with a guide RNA, exhibits a target mutation rate of 1 mutation per nucleotide per viral genome replication event.

### Claim 21 (depends on 1)

The method of claim 1, wherein the method comprises introducing into the eukaryotic cell a recombinant expression construct that comprises a nucleotide sequence encoding the fusion polypeptide.

### Claim 22 (depends on 21)

The method of claim 21, wherein the recombinant expression construct comprises a nucleotide sequence encoding the guide RNA.

### Claim 23

A method of modifying a target viral nucleic acid in the cytoplasm of a eukaryotic cell, the method comprising:
A) introducing into the eukaryotic cell gene editing components, wherein the gene editing components comprise:
a) a fusion polypeptide comprising: i) a CRISPR-Cas effector polypeptide; and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase and wherein one of the two or more heterologous polypeptides comprises a nuclear export signal (NES) polypeptide; and
b) one or more guide nucleic acids, wherein one or more guide nucleic acids comprise: i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide, thereby generating a modified eukaryotic cell; and
B) infecting the modified eukaryotic cell with a virus comprising the target viral nucleic acid, wherein the target viral nucleic acid is contacted with the gene editing components, and wherein said contacting provides for modification of the target viral nucleic acid.

### Claim 24

A system for modifying a target viral nucleic acid in the cytoplasm of a eukaryotic cell, the system comprising:
a1) a fusion polypeptide comprising: i) a CRISPR-Cas effector polypeptide that exhibits nickase activity; and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase that lacks all or a portion of a 3′-to-5′ exonuclease domain and/or lacks all or a portion of a 5′-to-3′ exonuclease domain, wherein one of the two or more heterologous polypeptides comprises a nuclear export signal (NES) polypeptide, and wherein the two or more heterologous polypeptides does not include a nuclear localization signal (NLS) polypeptide; and
b1) one or more guide nucleic acids, wherein one or more guide nucleic acids comprise: i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid, wherein the nucleotide sequence that binds to the target sequence has a length of from 15 nucleotides to 18 nucleotides; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide; or
a2) a nucleic acid comprising a nucleotide sequence encoding a fusion polypeptide comprising: i) a CRISPR-Cas effector polypeptide that exhibits nickase activity; and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase that lacks all or a portion of a 3′-to-5′ exonuclease domain and/or lacks all or a portion of a 5′-to-3′ exonuclease domain, wherein one of the two or more heterologous polypeptides comprises an NES polypeptide, and wherein the two or more heterologous polypeptides does not include an NLS polypeptide; and
b2) one or more guide nucleic acids, wherein one or more guide nucleic acids comprise: i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid, wherein the nucleotide sequence that binds to the target sequence has a length of from 15 nucleotides to 18 nucleotides; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide; or
a3) a nucleic acid comprising:
1) a first nucleotide sequence encoding a fusion polypeptide comprising: i) a CRISPR-Cas effector polypeptide that exhibits nickase activity; and ii) two or more heterologous polypeptides, wherein one of the two or more heterologous polypeptides is an error-prone DNA polymerase that lacks all or a portion of a 3′-to-5′ exonuclease domain and/or lacks all or a portion of a 5′-to-3′ exonuclease domain, wherein one of the two or more heterologous polypeptides comprises an NES polypeptide, and wherein the two or more heterologous polypeptides does not include an NLS polypeptide; and
2) a second nucleotide sequence encoding one or more guide nucleic acids, wherein one or more guide nucleic acids comprise: i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target viral nucleic acid, wherein the nucleotide sequence that binds to the target sequence has a length of from 15 nucleotides to 18 nucleotides; and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide.
